Hubei Vanz Pharm Co.,ltd.

 

warrantable quality,trustable service!

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
News
Home News

Merck’s Keytruda wins FDA breakthrough therapy status, priority review for first-line NSCLC

I'm Online Chat Now
China Hubei Vanz Pharm Co.,ltd certification
China Hubei Vanz Pharm Co.,ltd certification
I am very happy to cooperate with your company for nearly three years, thank you very attentive service, thank you for the excellent product quality.

—— Stephnie

You always have very fast delivery, very happy to cooperate with you. Thank you.

—— John

Very pleased to become your customer, and very happy for our cooperation, hope to be your long-term parter.

—— Sara

we received the package, very fast, the quality is very good, will continue to buy your products.

—— Luice

I have emailed you a couple times and they get returned as undeliverable. Yes. I am happy with the powders. thank you.

—— Bryan

Company News
Merck’s Keytruda wins FDA breakthrough therapy status, priority review for first-line NSCLC

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation and priority review to Merck’s Keytruda (pembrolizumab) for the first-line treatment of patients with advanced non–small cell lung cancer whose tumors express PD-L1.

 

latest company news about Merck’s Keytruda wins FDA breakthrough therapy status, priority review for first-line NSCLC  0The agency's action date (PDUFA) is 24 December 2016.

Merck has filed a marketing application in Europe for the similar indication.

The data supporting the submissions was generated in the Phase 3 Keynote-024 study under which Keytruda monotherapy demonstrated superior progression-free survival and overall survival compared to standard chemo.

Based on these results, Merck halted the trial early to offer patients on the chemotherapy arm the opportunity to receive Keytruda.

Merck Research Laboratories president Roger Perlmutter said: “Chemotherapy has been the foundation of first-line treatment for non-small cell lung cancer for decades, so the significant improvement in survival in patients with high PD-L1 expression seen with Keytruda compared to chemotherapy is welcome news.

“We appreciate the opportunity to work with regulatory authorities to make Keytruda a first-line treatment option in non-small cell lung cancer.”

Last month, the European Commission approved Keytruda to treat patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer (NSCLC) following at least 1 chemotherapy regimen.

Keytruda increases the ability of the body’s immune system to help identify and fight tumor cells.

It blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which could affect both tumor cells and healthy cells.

Pub Time : 2016-09-09 10:54:28 >> News list
Contact Details
Hubei Vanz Pharm Co.,ltd

Contact Person: Ms. Wendy Wang

Tel: +86 15927784577

Fax: 86-27-84492310

Send your inquiry directly to us